Institut Gustave Roussy: OncoSIGNal predicts resistance to AR targeted drugs in mCR prostate cancer

In collaboration with:

Naoual Menssouri and Yohann Loriot from Institut Gustave Roussy, published in Clinical Cancer Research their findings using OncoSIGNal for prostate cancer.

“Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors”.

It is shown that Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary androgen receptor axis inhibitors’ resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation.

Access article

Contact us

E-Mail us
Category group 1
  • Select all
Category group 2
  • Select all